Neuroprotective Therapy for Parkinson's Disease
- 31 March 1997
- journal article
- review article
- Published by Elsevier in Experimental Neurology
- Vol. 144 (1) , 24-28
- https://doi.org/10.1006/exnr.1996.6383
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidasePublished by Elsevier ,2004
- Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopaAnnals of Neurology, 1996
- The effect of deprenyl and levodopa on the progression of Parkinson's diseaseAnnals of Neurology, 1995
- Complex I, Iron, and ferritin in Parkinson's disease substantia nigraAnnals of Neurology, 1994
- The brain on fire?Annals of Neurology, 1994
- Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's diseaseAnnals of Neurology, 1994
- Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1993
- Superoxide dismutase and Parkinson's diseaseThe Lancet, 1990
- Effects of 1‐Methyl‐4‐Phenyl‐ 1,2,3,6‐Tetrahydropyridine and 1 ‐Methyl‐4‐Phenylpyridinium Ion on ATP Levels of Mouse Brain SynaptosomesJournal of Neurochemistry, 1990
- Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm studyJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1985